665 results on '"Tong, Hongyan"'
Search Results
2. Advances in biology, diagnosis and treatment of DLBCL
3. Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm
4. Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival
5. Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study
6. Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia
7. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report
8. Overcoming right heart failure through successful treatment of cardiac dominant diffuse large B-cell lymphoma: a case report
9. Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia
10. CCDC50, an essential driver involved in tumorigenesis, is a potential severity marker of diffuse large B cell lymphoma
11. Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes
12. Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis
13. Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis
14. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
15. Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia
16. The clinical impact of IKZF1 mutation in acute myeloid leukemia
17. Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective study
18. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
19. Clinical Characteristics and Prognosis of Patients with Follicular Lymphoma Grade 3A: A real-world study in a single centre
20. The treatment of patients with chronic myeloid leukemia chronic phase combined with myelofibrosis with tyrosine kinase inhibitors: A Chinese population-based study.
21. Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).
22. Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1 mutated de novo acute myeloid leukemia.
23. P-GEMOX with sequential or sandwiched radiotherapy for early-stage extranodal natural killer/T-cell lymphoma.
24. Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients
25. RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
26. Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes
27. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
28. Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
29. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era
30. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
31. MN1::ETV6‐positive de novo T‐cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
32. Inactivated Vaccine Dosage and Serum IgG Levels Correlate with Persistent COVID-19 Infection in Hematologic Malignancy Patients During the Omicron Surge in China
33. Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis
34. Real-world outcomes of the efficacy and safety of polatuzumab vedotin combination regimen in patients with relapsed/refractory diffuse large B cell lymphoma
35. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy
36. Effective management of a rare case of primary renal intravascular large B-cell lymphoma with modified R-CHOP regimen: A case report
37. The der(1;7)(q10;p10) defining a distinct profile from −7/del(7q) in myelodysplastic syndromes: A systematic review and meta‐analysis
38. Continuous Therapy in HHV-8 Negative Multicentric Castleman Disease: Pioneering Prolonged Progression-Free Survival
39. Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
40. Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
41. Prognosis influence of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia with t(15;17)(q24;q21)
42. Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact
43. Gilteritinib‐based combination therapy in adult relapsed/refractory FLT3‐mutated acute myeloid leukaemia
44. Intestinal ulcers in a patient with myelodysplastic syndrome: a case report
45. Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis
46. Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study
47. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia
48. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy
49. Analysis of clinical and molecular features of MDS patients with complex karyotype in China
50. Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.